Champions Oncology reported a strong third quarter, achieving record services revenue and maintaining positive adjusted EBITDA for the third consecutive quarter, despite a slight year-over-year decline in total revenue.

• Core study revenue reached a record $16.6 million, growing approximately 32% year-over-year.
• The company remains on track for full-year revenue growth and positive adjusted EBITDA while investing in data and drug discovery initiatives.
• Early momentum is evident in the data business with new deals closed and revenue expected in the fourth quarter.
• Champions is committed to maintaining disciplined capital allocation while investing for future growth without diluting shares.